Critically ill infants and children with influenza A (H1N1) in pediatric intensive care units in Argentina

Farias, Júlio A.; Fernández, A.; Monteverde, Ezequiel; Vidal, Nilda; Arias, Pilar; Montes, María José; Rodriguez, Giselle; Allasia, Mariela; Ratto, María E.; Jaén, R; Meregalli, Claudia; Fiqueprón, Karina; Calvo, Ana R.; Siaba, Alejandro; Albano, Lidia; Poterala, Rossana; Neira, Pablo; Esteban, Andrés

doi:10.1007/s00134-010-1853-1

Cited by 100 publications

(76 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar to figures reported in several other studies, 85.7% of the children in the present study were given oseltamivir. (8,(16)(17)(18)(19) The pandemic (H1N1) 2009 influenza virus caused severe illness, including ARDS and encephalitis, and resulted in 10.4% of the children being admitted to the intensive care unit. Although underlying medical conditions were common among the hospitalised children, we also identified cases of severe illness due to the H1N1 virus infection among children who were previously healthy.…”

Section: Discussionmentioning

confidence: 99%

Hospitalised Malaysian children with pandemic (H1N1) 2009 influenza: clinical characteristics, risk factors for severe disease and comparison with the 2002-2007 seasonal influenza

Koh

Loh

2016

smedj

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Hospitalised Malaysian children with pandemic (H1N1) 2009 influenza: clinical characteristics, risk factors for severe disease and comparison with the 2002-2007 seasonal influenza

Koh

Loh

2016

smedj

View full text Add to dashboard Cite

“…5 Oseltamivir treatment initiated within 24 hours of hospitalization was protective against death (P = .02) for 147 critically ill children in Argentina. 27 Delayed initiation of oseltamivir increased the likelihood of death for 193 children hospitalized with highly pathogenic avian influenza A (H5N1) virus infection, with a 75% increase in the adjusted OR for death for each day of delay. 28 Likewise, our review of nearly 800 critically ill children with influenza patients suggests improvement in survival with prompt NAI treatment.…”

Section: Discussionmentioning

confidence: 99%

Neuraminidase Inhibitors for Critically Ill Children With Influenza

et al. 2013

View full text Add to dashboard Cite

OBJECTIVE: Timely treatment with neuraminidase inhibitor (NAI) drugs appears to improve survival in adults hospitalized with influenza. We analyzed California surveillance data to determine whether NAI treatment improves survival in critically ill children with influenza. METHODS: We analyzed data abstracted from medical records to characterize the outcomes of patients aged 0 to 17 years hospitalized in ICUs with laboratory-confirmed influenza from April 3, 2009, through September 30, 2012. RESULTS: Seven hundred eighty-four influenza cases aged <18 years hospitalized in ICUs had information on treatment. Ninety percent (532 of 591) of cases during the 2009 H1N1 pandemic (April 3, 2009–August 31, 2010) received NAI treatment compared with 63% (121 of 193) of cases in the postpandemic period (September 1, 2010–September 30, 2012; P < .0001). Of 653 cases NAI-treated, 38 (6%) died compared with 11 (8%) of 131 untreated cases (odds ratio = 0.67, 95% confidence interval: 0.34–1.36). In a multivariate model that included receipt of mechanical ventilation and other factors associated with disease severity, the estimated risk of death was reduced in NAI-treated cases (odds ratio 0.36, 95% confidence interval: 0.16–0.83). Treatment within 48 hours of illness onset was significantly associated with survival (P = .04). Cases with NAI treatment initiated earlier in illness were less likely to die. CONCLUSIONS: Prompt treatment with NAIs may improve survival of children critically ill with influenza. Recent decreased frequency of NAI treatment of influenza may be placing untreated critically ill children at an increased risk of death.

show abstract

“…The results of a few studies in which the effects of oseltamivir treatment initiated for influenza were reported are summarized in Table 2 (33,36,38,40,(43)(44)(45)(46).…”

Section: Oseltamivir Treatment Time Of Initiation Of Treatment and Imentioning

confidence: 99%

Influenza and the use of oseltamivir in children

2016

View full text Add to dashboard Cite

Influenza is an infectious disease which causes significant morbidity and mortality. In the USA, approximately 200 000 hospital admissions and 36 000 deaths occur annualy due to severe influenza infections. Although influenza often causes a simple respiratory infection, it sometimes causes disorders affecting several organs including the lung, heart, brain, liver and muscles or serious life-threatening primary viral or secondary bacterial pneumonia. Currently, oseltamivir is the most important and effective drug for severe influenza infections. Severe influenza infections can be controlled and related deaths may be prevented with initiation of this drug especially within first 2 days. Oseltamivir is usually well tolerated and its most commonly reported side effect is related with the gastrointestinal system. In conclusion, the course of influenza changes in a positive direction and the rates of complications and mortality significantly reduce in patients in whom oseltamivir treatment is initiated as soon as possible. (Turk Pediatri Ars 2016; 51: 63-71)

show abstract

Critically ill infants and children with influenza A (H1N1) in pediatric intensive care units in Argentina

Abstract: In children with ARDS, H1N1 as an etiologic agent confers high mortality, and the presence of CCCs in such patients increases the risk of death.

Cited by 100 publications

References 30 publications

Hospitalised Malaysian children with pandemic (H1N1) 2009 influenza: clinical characteristics, risk factors for severe disease and comparison with the 2002-2007 seasonal influenza

Hospitalised Malaysian children with pandemic (H1N1) 2009 influenza: clinical characteristics, risk factors for severe disease and comparison with the 2002-2007 seasonal influenza

Neuraminidase Inhibitors for Critically Ill Children With Influenza

Influenza and the use of oseltamivir in children

Contact Info

Product

Resources

About